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Abstract
The process of angiogenesis is a vital step towards the formation of malignant tumors. Anti-
angiogenic peptides are therefore promising candidates in the treatment of cancer. In this
study, we have collected anti-angiogenic peptides from the literature and analyzed the resi-
due preference in these peptides. Residues like Cys, Pro, Ser, Arg, Trp, Thr and Gly are
preferred while Ala, Asp, Ile, Leu, Val and Phe are not preferred in these peptides. There is
a positional preference of Ser, Pro, Trp and Cys in the N terminal region and Cys, Gly and
Arg in the C terminal region of anti-angiogenic peptides. Motif analysis suggests the motifs
“CG-G”, “TC”, “SC”, “SP-S”, etc., which are highly prominent in anti-angiogenic peptides.
Based on the primary analysis, we developed prediction models using different machine
learning based methods. The maximum accuracy and MCC for amino acid composition
based model is 80.9% and 0.62 respectively. The performance of the models on indepen-
dent dataset is also reasonable. Based on the above study, we have developed a user-
friendly web server named “AntiAngioPred” for the prediction of anti-angiogenic peptides.
AntiAngioPred web server is freely accessible at http://clri.res.in/subramanian/tools/
antiangiopred/index.html (mirror site: http://crdd.osdd.net/raghava/antiangiopred/).
Introduction
The process of growth of new capillary blood vessels is used for healing and reproduction,
which is known as angiogenesis. It occurs for healing wounds and for restoring blood flow to
tissues after injury. The control of angiogenesis is achieved by maintaining balance between
growth and inhibitory factors in healthy tissues [1, 2]. Angiogenesis is regulated by ‘on’ and
‘off’, switches. Angiogenesis-stimulating growth factors are considered as ‘on switches’ while
the angiogenesis inhibitors are considered as the ‘off switches’. Excess production of angiogenic
growth factors favors the growth of blood vessels while the presence of excess of angiogenic
inhibitors prevents angiogenesis. Recent studies have identified several endogenous anti-angio-
genic peptides identified from various biological sources, which regulate angiogenesis and
tumor growth [3–6].
There are several peptides derived from various proteins, which inhibit angiogenesis [3,
4, 7–12]. Matrix Metalloproteinase also generates angiogenic inhibitors in vitro by proteolyti-
cally cleaving fragments from the pericellular matrix to generate endostatin, tumstatin,
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angiostatinetc [13]. These peptides inhibit endothelial cell proliferation, migration, tube forma-
tion and matrigel neovascularization. For example, the anti-angiogenic properties of arresten
are mediated through α1β1 integrin [7]. Recently, novel anti-angiogenic activity was localized
to amino acids 54–132 using deletion mutagenesis of tumstatin [9]. The peptides, similar to
tumstatin and the tum-5 domain, bind and function via αvβ3 in an RGD-independent
manner.
The increasing interest in peptide based therapeutics has led to the development of many
peptide databases with therapeutic properties like anticancer [14], antihypertensive [15], anti-
microbial [16], blood-brain barrier [17], antiparasitic [18], hemolytic [19], quorum-sensing
[20], tumor homing [21] and cell penetrating [22]. So far, peptide based drugs have been
employed for many diseases and these are being investigated in clinical applications against
tumors, either for imaging or therapy [3, 23–26]. In general, they are attractive molecules as
therapeutics because of their natural availability, ability to penetrate cells, specific target bind-
ing, and diverse modifications giving flexibility for different applications. The discovery of
angiogenesis peptide inhibitors will help in the development of therapeutic treatments against
cancer. Several web-based tools are available for the annotation of protein sequence to under-
stand the family and subfamily of the protein [27–29]. So far, there are no web-based tools to
predict the anti-angiogenic peptides. Thus, the search of anti-angiogenic agents for the treat-
ment of cancer is particularly important. Hence, in this study, a systematic attempt has been
made to develop machine learning based models using various features extracted from peptide
sequences like binary profile patterns (BPP); amino acid composition (AAC) as well as dipep-
tide compositions (DPC). A user-friendly web server has also been developed to help the exper-
imental biologist to predict the anti-angiogenic peptides.
Methods
Datasets
Positive dataset. The main dataset was collected from the literature. In this study, we have
obtained 257 anti-angiogenic peptides from various research articles and patents (S5 Table).
Due to the redundancy in the sequences, CD-HIT software was used to eliminate highly similar
sequences and it was ensured that no two sequences have more than 70% sequence identity.
The resulting dataset contains 135 sequences in the positive dataset (S1 Table). Among these
135 sequences, 20% of the dataset (~28 sequences) was kept separately to be used as indepen-
dent dataset (S3 Table).
Negative dataset. As there is no source of experimentally proven non-anti-angiogenic
peptides, we extracted 135 random peptide regions from proteins from Swiss-Prot database
[30] and treated them as non-anti-angiogenic peptides (S1 Table). Though some of these ran-
domly selected peptides could be anti-angiogenic in nature but the probability is very less. The
random peptide sequences were extracted in such a way that the length distribution of the data-
set remains same as of positive dataset. Among these 135 sequences, 20% of the dataset (~28
sequences) was kept separately to be used as independent dataset.
Terminus datasets. We divided the main dataset into nine terminus datasets, which are
NT5, CT5, NTCT5, NT10, CT10, NTCT10, NT15, CT15 and NTCT15. NT5 and CT5 contain
first five residues and last five residues from the N-terminal and C-terminal region of the pep-
tide sequence respectively. NTCT5 is obtained by joining the NT5 and CT5 sequence. Similarly
other terminus datasets were also constructed to understand the region of the peptide contain-
ing maximum information to discriminate these peptides from random sequence.
Independent dataset. The independent dataset was made by extracting 20% of the
sequences (~28 sequences) from the positive, as well as negative dataset, thereby making a total
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of 56 sequences (S2 Table). These sequences were not used in either training or testing proce-
dure while developing any model.
Random datasets. In order to check the reliability of models, we created five more random
negative dataset using the same procedure as used in developing negative dataset. These data-
sets have been created to check whether the property of the developed model changes if the
negative dataset is replaced with another randomly created dataset. These datasets were named
as ‘Random1’, ‘Random2’, ‘Random3’, ‘Random4’ and ‘Random5’ (S4 Table).
Calculation of residue propensities. The propensity of each amino acid in anti-angio-
genic peptides was calculated by the following formula:
PðiÞ ¼ AACpðiÞ
AACpðiÞ þ AACsðiÞ ðEq 1Þ
where, P(i) represents propensity of ith amino acid, AACp(i) and AACs(i) represents the aver-
age composition of ith amino acid in positive and Swiss-Prot dataset, respectively. We also cal-
culated the position wise propensities of amino acids in both N-terminal and C-terminal
regions of the peptides.
Cross validation technique. In the present study, we performed ten-fold cross-validation
technique to develop our models. In this technique, the sequences were randomly divided into
ten sets. Nine sets were used for training the model while the remaining tenth set was used for
testing. The process was then repeated ten times such that each set was once used as a test set.
The average performance of all the ten sets is reported as the final performance of the method.
Machine learning approaches. Different machine learning techniques like Support Vector
Machines (SVM), Neural Networks (Multilayer Perceptron), Bayesian approach (Naïve Bayes)
[31], Nearest Neighbor (IBk) [32], Decision trees (Random Forest and J48) [33, 34] and logistic
regression [35] were used to develop the models. SVM based method was implemented using
SVMLight software [36] while rest of the methods were implemented using WEKA package
[37].
Input features for prediction. Amachine learning based method requires set of features
in the form of numbers as input. These features contain the global information of the biological
molecules being studied by the method. The features used in this study are described below.
Amino acid composition (ACC). It is represented by the percentage of each amino acid
within a peptide with a vector size of 20. It was calculated by using the following equation:
ACCðiÞ ¼ Ai
N
X10 ðEq 2Þ
Where AAC(i) represent the percentage of amino acid (i); Ai represent the frequency of i
th resi-
due and N is the total number of residues in the peptide.
Dipeptide composition. Dipeptide composition refers to the percentage of all the possible
pair of amino acids (e.g. AA, AC, AD etc.) present in the peptide. It represents a vector size of
400 (20 x 20) and also includes information about the neighboring residues. It was calculated
using the following equation:
DPCðiÞ ¼ DPðiÞ
N
ðEq 3Þ
Where DPC (i) represents the percentage of dipeptide (i); DP (i) represents the frequency of ith
dipeptide and N represents the total number of dipeptides.
Binary profile. In binary profile, each amino acid is represented by a binary vector of size
20 where one element of the vector corresponding to the presence of a particular amino acid is
represented by 1 and other 19 elements are represented by 0. (e.g. Ala by
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1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0). Therefore for a stretch of 5 amino acids, the total vector
size of binary profile will be 100 (20 x 5).
Two sample logos. Online service of two sample logo software was used to generate two
sample logos [38–40]. It is useful in representing the frequency of amino acids at specific posi-
tions in the peptide sequence. The size of the residues displayed at each position is proportional
to the relative frequency of each amino acid at that position.
Performance measures. The performance of the developed models was calculated using
the standard performance parameters like Sensitivity (Sn), Specificity (Sp), Accuracy (Acc) and
Matthew’s correlation coefficient (MCC). The formula to calculate Sensitivity, Specificity,
Accuracy and MCC is given by following equations:
Sensitivity ¼ TPðTP þ FNÞ ðEq 4Þ
Specificity ¼ TNðTN þ FPÞ ðEq 5Þ
Accuracy ¼ ðTP þ TNÞðTP þ FP þ TN þ FNÞX 100 ðEq 6Þ
MCC ¼ ðTPÞðTNÞ  ðFPÞðFNÞffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiðTP þ FNÞðTN þ FPÞðTP þ FPÞðTN þ FNÞp ðEq 7Þ
Where TP, TN, FP and FN represents True Positive, True Negative, False Positive and False
Negative respectively.
Results
Amino acid composition analysis
The amino acid composition analysis was carried out to extract certain residues, which are
dominant in anti-angiogenic peptides. We compared the average amino acid composition in
anti-angiogenic and non-anti-angiogenic peptides (Fig 1). It was observed that residues like
Cys, Pro, Ser, Arg, Trp, Thr and Gly are predominant in anti-angiogenic peptides while resi-
dues Ala, Asp, Ile, Leu, Val and Phe are under-represented in these peptides. Composition was
also computed for all the random datasets and compared with the negative dataset and no bias
was observed, ensuring that the dataset is purely random. We also calculated the average
amino acid composition of the entire Swiss-Prot database to be used as reference for analyzing
the difference (Fig 1).
Residue propensities and positional preference
The propensities of residues are in accordance with the amino acid composition analysis with
Cys, Trp, Ser, Arg and Pro being predominant in anti-angiogenic peptides while Val, Ala, Leu
and Ile being less preferred in these peptides (S6 Table). To understand the position wise pref-
erence of amino acids at the first and last 10 residues of the N and C terminus of anti-angio-
genic peptides, we calculated the position wise propensities using Swiss-Prot as reference
dataset (S7 Table). Cys, Ser, Thr and His are preferred at N1 position; Pro at N2 position; Trp
and Pro at N3; Ser and Phe at N4 and Cys is predominant at N5, N6 and N7 positions in anti-
angiogenic peptides. At C-terminal region, Cys is prominent at C1 and C2; Gly and Cys at C3
and C4; Cys at C5 while Arg is most favoured at C8, C9 and C10 position. We also performed
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residue based preference analysis using two sample logo (S1 and S2 Fig), which is in accordance
with the results described above.
Motif analysis
To find the frequent motifs in the anti-angiogenic peptides, we extracted the motifs using
MERCI software using following criteria: i) the motif should be present in at least 10% (~14
peptides) of the total number of peptides in the positive dataset, ii) the motif can have a maxi-
mum of 5 gaps. Here, the gap represents the presence or absence of any amino acid. Using the
above criteria, we obtained a total of 151 motifs. Further, we selected the motifs, which had
propensity (Eq 1) more than or equal to 0.90. This resulted in a total of 22motifs, which are
"CG-G", "TC", "SC", "SP-S", "W-S-C", "WS-C", "S-T-C", "S-C-S", "CS-T", "C-S-T", "T-C", "S-C",
Fig 1. Amino acid composition analysis of the residues in anti-angiogenic and non-anti-angiogenic peptides.Composition of entire Swiss-Prot is
taken for reference and composition of all random datasets.
doi:10.1371/journal.pone.0136990.g001
A Server for Prediction of Anti-Angiogenic Peptides
PLOS ONE | DOI:10.1371/journal.pone.0136990 September 3, 2015 5 / 13
"C-G-G", "TR", "S-T-G", "S-P-S", "SP", "RT", "P-W", "P-C", "C-N" and "CG" (hyphen ‘-’ repre-
sents a gap).These motifs are important for understanding and identification of anti-angio-
genic peptides. The full list of 151 motifs sorted by propensity is given in S8 Table.
Performance of various machine learning approaches on the dataset
We used different machine learning classifiers like SVM, Random Forest (RF), IBk, J48, Naïve
Bayes, Logistic and Multilayer Perceptron (MP) to develop amino acid composition based
model on whole peptide dataset. This helps us to compare the performance of different classifi-
ers on the same dataset. The models developed in this study are explained below.
Amino acid composition based model
We used amino acid composition of the peptide as input feature to develop the prediction
model using SVM, J48, RF, Naïvebayes, MP, Logistic and IBk machine learning classifiers
(Table 1).SVM (MCC = 0.48), MP (MCC = 0.49) and RF(MCC = 0.48) based models per-
formed better than other methods. The performance among the best models (SVM, RF, MP)
was alike and therefore we selected SVMmachine learning method for further development of
models using different input features.
The performance of SVM based models developed on the terminus datasets is summarized
in Table 2. We observed that the best results in terms of accuracy (80.9%) and MCC (0.62) are
Table 1. Performance of various machine learning classifiers using amino acid composition as input
feature on whole peptide dataset.
Methods Sn (%) Sp (%) Acc (%) MCC
SVM 69.2 78.5 73.8 0.48
IBk 69.2 74.8 72.0 0.44
Random Forest 70.1 77.6 73.8 0.48
Logistic 70.1 74.8 72.4 0.45
Multilayer Perceptron 70.1 78.5 74.3 0.49
Naïve Bayes 65.4 72.0 68.7 0.37
J48 62.6 73.8 68.2 0.37
Sn: Sensitivity; Sp: Specificity; Acc: Accuracy; MCC: Matthew’s Correlation Coefficient.
doi:10.1371/journal.pone.0136990.t001
Table 2. Performance of SVM basedmodels using amino acid composition as input feature on nine
terminus datasets.
Approach Sn (%) Sp (%) Acc (%) MCC
NT5 69.2 72.0 70.6 0.41
CT5 62.9 68.2 65.6 0.31
NTCT5 72.0 71.0 71.5 0.43
NT10 71.0 76.6 73.8 0.48
CT10 69.8 70.1 70.0 0.40
NTCT10 68.2 76.6 72.4 0.45
NT15 79.0 82.7 80.9 0.62
CT15 67.9 72.8 70.4 0.41
NTCT15 75.3 80.3 77.8 0.56
Sn: Sensitivity; Sp: Specificity; Acc: Accuracy; MCC: Matthew’s Correlation Coefficient.
doi:10.1371/journal.pone.0136990.t002
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obtained on NT15 terminus dataset. The results on CT5 terminus dataset had least accuracy
(65.6%) and MCC (0.31). The results indicate that the major functional properties of these pep-
tides are contained in the N-terminal residues of the peptide sequence.
Dipeptide composition based model
SVM based model was developed using dipeptide composition of the whole peptide as input
feature and we achieved an accuracy of 74.8% with MCC 0.50 (Table 3). We also developed
models on nine terminus datasets as done previously. The maximum accuracy (75.9%) and
MCC (0.52) was obtained on CT15 terminus dataset although the performance on NT15
(74.1% accuracy) was also nearby. There was a slight increase in the performance of dipeptide
composition based model (74.8% accuracy) as compared to amino acid composition based
model (73.8% accuracy) on whole peptide dataset.
Binary profile based model
We also developed SVM based models using binary profile of peptide as input feature. We
achieved the best accuracy (77.6%) and MCC (0.55) on NTCT5 terminus dataset (Table 4).
Table 3. Performance of SVM basedmodels using dipeptide composition as input feature on whole
peptide dataset and nine terminus datasets.
Approach Sn(%) Sp (%) Acc (%) MCC
Whole peptide 75.7 73.8 74.8 0.50
NT5 66.4 66.4 66.4 0.33
CT5 57.1 57.9 57.6 0.15
NTCT5 64.5 60.8 62.6 0.25
NT10 70.1 73.8 72.0 0.44
CT10 63.2 70.1 66.7 0.33
NTCT10 65.4 74.8 70.1 0.40
NT15 75.3 72.8 74.1 0.48
CT15 74.1 77.8 75.9 0.52
NTCT15 72.8 76.5 74.7 0.49
Sn: Sensitivity; Sp: Specificity; Acc: Accuracy; MCC: Matthew’s Correlation Coefficient.
doi:10.1371/journal.pone.0136990.t003
Table 4. Performance of SVM basedmodels using binary profile as input feature on nine terminus
datasets.
Approach Sn(%) Sp (%) Acc (%) MCC
NT5 66.4 72.9 69.7 0.39
CT5 68.6 69.2 68.9 0.38
NTCT5 75.7 79.4 77.6 0.55
NT10 65.4 72.0 68.7 0.37
CT10 55.7 61.7 58.7 0.17
NTCT10 65.4 71.0 68.2 0.37
NT15 70.4 72.8 71.6 0.43
CT15 69.1 71.6 70.4 0.41
NTCT15 71.6 76.5 74.1 0.48
Sn: Sensitivity; Sp: Specificity; Acc: Accuracy; MCC: Matthew’s Correlation Coefficient.
doi:10.1371/journal.pone.0136990.t004
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Binary profile based models performed poor on both NT15 and CT15 terminus datasets with
MCC of 0.43 and 0.41 respectively.
Performance on independent dataset
In order to validate the models, the performances of all the best models were tested on an inde-
pendent dataset. The amino acid and dipeptide composition based models, both achieved accu-
racy 69.6% with MCC 0.41 on whole peptide dataset (Table 5). The model based on amino acid
composition on NT15 terminus dataset achieved accuracy 75.0% with MCC 0.51. These results
indicate that our models are robust and performed equally well on the independent dataset.
Reliability of models
We created five random datasets (Random-1–5) and developed amino acid composition based
model using positive dataset and each of the random datasets generating a total of 5 models.
The performance of these models is given in Table 6. The results indicate that the developed
models are reliable and stable enough to perform well in all the random datasets.
Implementation of web server
Based on the above study and to assist the scientific community, we developed a web server
named ‘AntiAngiopred’ with user-friendly interface. We implemented two models in the web
server; i) amino acid composition based model on N15 terminus dataset, ii) amino acid compo-
sition based model on whole peptide dataset. The former model is implemented due to its best
performance among other models and the latter is implemented for peptides which are less
than 15 residues in length. Due to the limited number of anti-angiogenic peptide sequences,
the models implemented in the web server are developed using all the sequences. A user can
Table 5. Performance of SVM basedmodels on independent dataset.
Approach Feature Sn (%) Sp (%) Acc (%) MCC
Independent Dataset
Whole peptide AAC 53.6 85.7 69.6 0.41
Whole peptide DPC 64.3 75.0 69.6 0.41
NT15 AAC 65.0 85.0 75.0 0.51
Sn: Sensitivity; Sp: Specificity; Acc: Accuracy; MCC: Matthew’s Correlation Coefficient.
doi:10.1371/journal.pone.0136990.t005
Table 6. Performance of SVM basedmodels using amino acid composition as input feature on differ-
ent random dataset taken as negative dataset.
Dataset Sn (%) Sp (%) Acc (%) MCC
Random Datasets
Random1 70.1 71.8 71.0 0.42
Random2 70.1 79.4 74.8 0.50
Random3 75.7 77.6 76.6 0.53
Random4 75.7 81.3 78.5 0.57
Random5 72.9 73.8 73.4 0.47
Sn: Sensitivity; Sp: Specificity; Acc: Accuracy; MCC: Matthew’s Correlation Coefficient.
doi:10.1371/journal.pone.0136990.t006
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submit the peptide sequence in the ‘Predict’ module of the web server and can predict whether
his/her peptide has anti-angiogenic property or not. User can also get the single mutant analogs
of the submitted peptide along with their prediction. It will also help a user to identify mini-
mummutations and their location in a peptide sequence so as to have anti-angiogenic proper-
ties in that peptide. If a user has multiple peptides then ‘Multiple Peptide’ module helps him/
her to predict the anti-angiogenic nature of all of his/her peptides using a single submission
form. The web service can be accessed at http://clri.res.in/subramanian/tools/antiangiopred/ or
at its mirror site at http://crdd.osdd.net/raghava/antiangiopred/
Discussion
In this study an attempt has been made to develop an effective in silico method to predict anti-
angiogenic peptides. We used a dataset of 107 positive and 107 negative sequences to develop
models and check performance of models using ten-fold cross validation technique. We also
tested the performance of the developed models on the independent dataset with 28 positive
and 28 negative sequences. Primary analysis based on the amino acid composition and residue
propensities reveal that the residues such as Cys, Trp, Ser, Arg and Pro are preferred in anti-
angiogenic peptides while Val, Ala, Ile and Asp are not preferred in these peptides. Analysis of
two sample logos and positional preference show that the predominance of certain residues
like Ser, Pro, Trp and Cys in the N-terminal region of anti-angiogenic peptides, while in the C-
terminus, the residues such as Cys, Gly and Arg were found. Both Ser and Cys have high pro-
pensities while Ala and Val have low propensities at most of the positions in the N-terminal
region. In C-terminal region, Arg, His and Cys have high propensities while Ala has low pro-
pensity at most of the positions. Further, motif analysis suggests the prominent motifs like
"CG-G", "TC", "SC", "SP-S", "W-S-C", "WS-C", etc., which are present in the anti-angiogenic
peptides. Based on the primary analysis, we developed models for discriminating anti-angio-
genic and non-anti-angiogenic peptides using different machine learning techniques. The
SVM based models developed in this study, were able to discriminate anti-angiogenic and non-
anti-angiogenic peptides with 80.9% accuracy and 0.62 MCC on NT15 dataset using amino
acid composition as input feature. On an independent dataset, the above model achieved 75%
accuracy and 0.51 MCC. Further, the performance of amino acid composition based models
on whole peptide dataset developed using all the random datasets indicate that the model is sta-
ble and hence reliable. To assist and help the scientific community, we have integrated the
models developed in this study in the web server AntiAngioPred, which can be accessed at
http://clri.res.in/subramanian/tools/antiangiopred/index.html (mirror site: http://crdd.osdd.
net/raghava/antiangiopred/)
Limitations and future development
The current study is based on the small size of the dataset of anti-angiogenic peptides. There-
fore, the predictor may not be robust enough to apply on a very diverse set of peptides as com-
pared to the dataset used in this study. As soon as more and more anti-angiogenic peptides will
be made available in the literature, the predictor will require retraining on the new dataset to
make it more robust. The choice of random peptides as negative dataset poses a further limita-
tion on this predictor. Ideally, a negative dataset should have experimentally validated non
anti-angiogenic peptides. However, in the absence of non anti-angiogenic peptides, a more
appropriate choice would be random peptides having similar physico-chemical properties as
that of anti-angiogenic peptides. The above suggestions should be considered for the future
development of models.
A Server for Prediction of Anti-Angiogenic Peptides
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